Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balovaptan - Roche

Drug Profile

Balovaptan - Roche

Alternative Names: RG-7314; RO 5028442; RO 5285119

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antipsychotics; Anxiolytics; Behavioural disorder therapies; Benzodiazepines; Pyridines; Small molecules; Triazoles; Vascular disorder therapies
  • Mechanism of Action Vasopressin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke
  • Discontinued Pervasive child development disorders; Post-traumatic stress disorders

Most Recent Events

  • 15 Feb 2024 Discontinued - Phase-II for Post-traumatic stress disorders in USA (PO) (Roche pipeline, February 2024)
  • 05 Oct 2023 Roche completes the phase-II trial in Post-traumatic stress disorders in USA (PO) (NCT05401565)
  • 07 Aug 2023 Hoffmann-La Roche withdrew a phase-II trial prior to enrolment in Stroke (In adults, In the elderly) in USA and Spain (IV) due to sponsor's decision (NCT05399550)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top